Trials / Completed
CompletedNCT00519558
Growth Hormone Deficiency in Adults (GHDA)
Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Japan. The aim of this trial is to demonstrate superiority of the effect of NN-220 compared with that of placebo as assessed by the change in percent in truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with Growth Hormone Deficiency in Adults (GHDA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin |
Timeline
- Start date
- 2003-05-31
- Primary completion
- 2005-01-24
- Completion
- 2005-01-24
- First posted
- 2007-08-22
- Last updated
- 2017-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00519558. Inclusion in this directory is not an endorsement.